Astellas Pharma (YPH) Financial Statements
Astellas Pharma Financial Overview
Astellas Pharma's market cap is currently $26.22B. The company's EPS TTM is $69.71; its P/E ratio is 12.62; and it has a dividend yield of 3.43%. Astellas Pharma is scheduled to report earnings on November 4, 2026, and the estimated EPS forecast is $0.37. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.91T | $ 2.14T | $ 1.60T | $ 1.52T | $ 1.30T |
| Gross Profit | $ 1.56T | $ 1.59T | $ 1.31T | $ 1.23T | $ 1.04T |
| Operating Income | $ 255.67B | $ 419.70B | $ 178.07B | $ 285.43B | $ 220.02B |
| EBITDA | $ 462.67B | $ 585.25B | $ 282.45B | $ 337.39B | $ 297.83B |
| Net Income | $ 50.75B | $ 291.54B | $ 17.05B | $ 98.71B | $ 124.09B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 188.37B | $ 281.61B | $ 335.69B | $ 376.84B | $ 315.99B |
| Total Assets | $ 3.34T | $ 3.57T | $ 3.57T | $ 2.46T | $ 2.33T |
| Total Debt | $ 937.09B | $ 565.95B | $ 1.01T | $ 200.01B | $ 212.74B |
| Net Debt | $ 748.71B | $ 284.35B | $ 670.03B | $ -176.83B | $ -103.24B |
| Total Liabilities | $ 1.83T | $ 1.74T | $ 1.97T | $ 948.56B | $ 872.09B |
| Stockholders' Equity | $ 1.51T | $ 1.83T | $ 1.60T | $ 1.51T | $ 1.46T |
| Cash Flow | |||||
| Free Cash Flow | $ 164.61B | $ 508.53B | $ 143.27B | $ 295.88B | $ 227.42B |
| Operating Cash Flow | $ 201.61B | $ 566.25B | $ 181.32B | $ 332.32B | $ 258.16B |
| Investing Cash Flow | $ -96.52B | $ -72.78B | $ -854.65B | $ -89.06B | $ -63.13B |
| Financing Cash Flow | $ -261.37B | $ -404.78B | $ 614.06B | $ -195.62B | $ -216.30B |
Currency in JPY